"Neuraminidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992)
| Descriptor ID |
D009439
|
| MeSH Number(s) |
D08.811.277.450.692
|
| Concept/Terms |
Neuraminidase- Neuraminidase
- Exo-alpha-Sialidase
- Exo alpha Sialidase
- Sialidase
- N-Acylneuraminate Glycohydrolases
- Glycohydrolases, N-Acylneuraminate
- N Acylneuraminate Glycohydrolases
- Oligosaccharide Sialidase
- Sialidase, Oligosaccharide
|
Below are MeSH descriptors whose meaning is more general than "Neuraminidase".
Below are MeSH descriptors whose meaning is more specific than "Neuraminidase".
This graph shows the total number of publications written about "Neuraminidase" by people in this website by year, and whether "Neuraminidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 3 | 0 | 3 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuraminidase" by people in Profiles.
-
Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface. Immunity. 2024 Jun 11; 57(6):1413-1427.e9.
-
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment. Clin Infect Dis. 2022 02 11; 74(3):532-540.
-
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022 05; 22(5):718-730.
-
Intermittent enzyme replacement therapy with recombinant human ?-galactosidase prevents neuraminidase 1 deficiency J Biol Chem. 2020 09 25; 295(39):13556-13569.
-
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. Cell Host Microbe. 2019 12 11; 26(6):715-728.e8.
-
Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host Microbe. 2019 12 11; 26(6):729-738.e4.
-
Antibody Determinants of Influenza Immunity. J Infect Dis. 2019 04 08; 219(Suppl_1):S21-S29.
-
Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. J Virol. 2015 Apr; 89(7):3737-45.
-
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J. 2015 Jun; 45(6):1642-52.
-
Intrinsically de-sialylated CD103(+) CD8 T cells mediate beneficial anti-glioma immune responses. Cancer Immunol Immunother. 2014 Sep; 63(9):911-24.